SCHEDULE: Bain Capital Updates NewAmsterdam Pharma Stake; Director Resigns
Schedule 13D Amendment
Bain Capital entities filed an amended Schedule 13D for NewAmsterdam Pharma, maintaining a 9.99% beneficial ownership stake, while Nicholas Downing resigned from the board.
Summary
- Bain Capital entities, including BCLS Fund III Investments, LP, continue to collectively beneficially own 11,422,504 Ordinary Shares of NewAmsterdam Pharma Company N.V.
- This represents 9.99% of the outstanding Ordinary Shares, calculated based on 113,390,804 shares outstanding as of October 31, 2025, and 848,591 shares issuable from Pre-Funded Warrants, subject to a 9.99% beneficial ownership blocker.
- Nicholas Downing resigned from NewAmsterdam Pharma's Board of Directors and its committees, effective November 5, 2025.
- The filing is Amendment No. 4 to the initial Schedule 13D filed on December 2, 2022.
Sentiment
Score: 5
Explanation: The filing is largely administrative, detailing an updated beneficial ownership stake that remains consistent due to a blocker, and a director resignation. There are no explicit positive or negative financial or operational developments disclosed.
Future Outlook
NA
Industry Context
This filing is an administrative update regarding a significant investor's stake and a board change for a pharmaceutical company. It does not provide information to assess broader industry trends or competitive landscape.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director, Board of Directors and its committees | Nicholas Downing | NA | 2025-11-05 | Resignation |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Composition | Nicholas Downing resigned from the Issuer's Board of Directors and its committees. | 2025-11-05 | Reduces the number of directors on the board and relevant committees. The impact on governance depends on whether a replacement is sought and the strategic role of the departing director. |
Stakeholder Impact
- Shareholders: The beneficial ownership by Bain Capital remains significant at 9.99%, indicating continued institutional interest. The resignation of a director may lead to questions regarding board composition and strategic direction, though no specific reason for resignation was provided.
Key Dates
| Date | Description |
|---|---|
| 2022-12-02 | Initial Schedule 13D filed by Reporting Persons. |
| 2023-06-13 | Amendment No. 1 to Schedule 13D filed. |
| 2024-03-01 | Amendment No. 2 to Schedule 13D filed. |
| 2024-12-17 | Amendment No. 3 to Schedule 13D filed. |
| 2025-10-31 | Date as of which 113,390,804 Ordinary Shares were issued and outstanding, as reported by the Issuer in its Quarterly Report on Form 10-Q. |
| 2025-11-05 | Effective date of Nicholas Downing's resignation from the Issuer's Board of Directors and its committees. |
| 2025-11-05 | Date the Issuer's Quarterly Report on Form 10-Q for the period ended September 30, 2025, was filed with the SEC. |
| 2025-11-07 | Date of signature for the current Schedule 13D Amendment No. 4. |
Recommendation
holdThis filing is primarily an administrative update to an existing Schedule 13D, confirming Bain Capital's continued significant, but capped, beneficial ownership in NewAmsterdam Pharma. The resignation of a director, while a governance change, is not accompanied by any information suggesting a material shift in company strategy or financial performance. As such, the filing provides no new fundamental information that would warrant a change in investment thesis, leading to a 'hold' recommendation.
Keywords
NewAmsterdam Pharma, Bain Capital, Schedule 13D, Beneficial Ownership, Director Resignation, Ordinary Shares, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.